

Sarah Lw Norris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4977961/publications.pdf>

Version: 2024-02-01

32
papers

1,071
citations

361413

20
h-index

414414

32
g-index

32
all docs

32
docs citations

32
times ranked

1416
citing authors

#	ARTICLE	IF	CITATIONS
1	The Natural History of Aerosolized <i>Francisella tularensis</i> Infection in <i>Cynomolgus</i> Macaques. <i>Pathogens</i> , 2021, 10, 597.	2.8	4
2	Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine. <i>Vaccine</i> , 2021, 39, 2780-2790.	3.8	7
3	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. <i>Scientific Reports</i> , 2021, 11, 19458.	3.3	9
4	Comparison of Rectal and Infrared Thermometry Temperatures in Anesthetized Swine (<i>Sus</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	1.2	11
5	The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity. <i>Frontiers in Immunology</i> , 2020, 11, 555464.	4.8	2
6	Zika Virus Infection in Syrian Golden Hamsters and Strain 13 Guinea Pigs. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 864-867.	1.4	18
7	Accurate virus quantitation using a Scanning Transmission Electron Microscopy (STEM) detector in a scanning electron microscope. <i>Journal of Virological Methods</i> , 2017, 248, 136-144.	2.1	19
8	High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus. <i>Emerging Infectious Diseases</i> , 2017, 23, 1274-1281.	4.3	74
9	Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates. <i>Vaccine</i> , 2016, 34, 523-530.	3.8	39
10	Lateral Flow Immunoassays for Ebola Virus Disease Detection in Liberia. <i>Journal of Infectious Diseases</i> , 2016, 214, S222-S228.	4.0	36
11	Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. <i>EBioMedicine</i> , 2016, 3, 67-78.	6.1	49
12	Safety and immunogenicity of ricin vaccine, RVEcâ,,ç, in a Phase 1 clinical trial. <i>Vaccine</i> , 2015, 33, 7299-7306.	3.8	26
13	Comparison of experimental respiratory tularemia in three nonhuman primate species. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2015, 39, 13-24.	1.6	26
14	Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates. <i>Viruses</i> , 2014, 6, 4666-4682.	3.3	22
15	CpG oligodeoxynucleotides augment the murine immune response to the <i>Yersinia pestis</i> F1-V vaccine in bubonic and pneumonic models of plague. <i>Vaccine</i> , 2009, 27, 2220-2229.	3.8	30
16	Pathogenesis of aerosolized Eastern Equine Encephalitis virus infection in guinea pigs. <i>Virology Journal</i> , 2009, 6, 170.	3.4	41
17	Application of Polysaccharide Microarray Technology for the Serodiagnosis of <i>Burkholderia pseudomallei</i> Infection (Meliodosis) in Humans. <i>Journal of Carbohydrate Chemistry</i> , 2008, 27, 32-40.	1.1	11
18	An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. <i>Vaccine</i> , 2008, 26, 4262-4266.	3.8	21

#	ARTICLE	IF	CITATIONS
19	Identification of a Surrogate Marker for Infection in the African Green Monkey Model of Inhalation Anthrax. <i>Infection and Immunity</i> , 2008, 76, 5790-5801.	2.2	36
20	Modified Caspase-3 Assay Indicates Correlation of Caspase-3 Activity with Immunity of Nonhuman Primates to <i>Yersinia pestis</i> Infection. <i>Vaccine Journal</i> , 2008, 15, 1134-1137.	3.1	20
21	Determination of Antibiotic Efficacy against <i>Bacillus anthracis</i> in a Mouse Aerosol Challenge Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1373-1379.	3.2	67
22	Severe Encephalitis in <i>Cynomolgus</i> Macaques Exposed to Aerosolized Eastern Equine Encephalitis Virus. <i>Journal of Infectious Diseases</i> , 2007, 196, 441-450.	4.0	60
23	Detection of the host immune response to <i>Burkholderia mallei</i> heat-shock proteins GroEL and DnaK in a glanders patient and infected mice. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 137-147.	1.8	28
24	Interleukin-12 induces a Th1-like response to <i>Burkholderia mallei</i> and limited protection in BALB/c mice. <i>Vaccine</i> , 2006, 24, 1413-1420.	3.8	33
25	Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. <i>Vaccine</i> , 2006, 24, 3654-3660.	3.8	41
26	An Assessment of Health Status among Medical Research Volunteers Who Served in the Project Whitecoat Program at Fort Detrick, Maryland. <i>Military Medicine</i> , 2005, 170, 183-187.	0.8	16
27	Protective Antigen and Toxin Neutralization Antibody Patterns in Anthrax Vaccinees Undergoing Serial Plasmapheresis. <i>Vaccine Journal</i> , 2005, 12, 713-721.	3.1	28
28	Validation of the anthrax lethal toxin neutralization assay. <i>Biologicals</i> , 2004, 32, 17-27.	1.4	80
29	Anthrax capsule vaccine protects against experimental infection?. <i>Vaccine</i> , 2004, 23, 43-47.	3.8	89
30	The use of a model of in vivo macrophage depletion to study the role of macrophages during infection with <i>Bacillus anthracis</i> spores. <i>Microbial Pathogenesis</i> , 2004, 37, 169-175.	2.9	75
31	One-Year Prospective Replication Study of an Untreated Sample of Community Dysthymia Subjects. <i>Journal of Nervous and Mental Disease</i> , 1994, 182, 396-401.	1.0	23
32	Comparison of a Community Dysthymia Sample at Screening with a Matched Group of Nondepressed Community Controls. <i>Journal of Nervous and Mental Disease</i> , 1994, 182, 402-407.	1.0	30